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Viral-induced neurodegenerative disease 
Michael J Buchmeier* and Thomas E Lane? 
Viral etiology has been postulated in a variety of neurological 
diseases in humans, including multiple sclerosis. Several 
experimental animal models of viral-induced neurodegenerative 
disease provide insight into potential host- and pathogen- 
dependent mechanisms involved in the disease process. Two 
such mouse models are the Theiler’s murine encephalomyelitis 
virus (TMEV) infection and mouse hepatitis virus (MHV) infection. 
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Abbreviations 
AG aminoguanidine 
CNS central nervous system 
EAE experimental allergic encephalomyelitis 
IFN interferon 
IL interleukin 
MCP-1 monocyte chemoattractant protein-l 
MHV mouse hepatitis virus 
MS multiple sclerosis 
NO nitric oxide 
NOS NO synthase 
TMEV Theiler’s murine encephalomyelitis virus 
TNF tumor necrosis factor 
Introduction 
Prevalent hypotheses to explain the etiology of multiple 
sclerosis (MS) suggest that an infectious agent encoun- 
tered during adolescence might prime a disease process 
that only appears in the adult after a variable period of 
quiescence [l]. Efforts to identify a causative agent of MS 
have focused on finding a single virus causally linked to 
MS; however, it is clear from a variety of experimental 
model systems that many viruses are capable of inducing 
Table 1 
Viruses associated with demyelinating disease. 
Virus Family Host 
Mouse hepatitis virus Coronavirus 
Theiler’s virus Picornavirus 
Measles virus Paramyxovirus 
Canine distemper Paramyxovirus 
Mouse, rat 
Mouse 
Man 
Dog 
Semliki forest virus 
Visna 
HTLV- 1 
HIV 
Marck’s disease virus 
HSV-1 
JC virus 
Alphavirus 
Lentivirus 
Lentivirus 
Lentivirus 
Herpesvirus 
Herpesvirus 
Papopavirus 
Mouse 
Sheep 
Man 
Man 
Turkey 
Man 
Man 
demyelinating syndromes (Table 1). Because of their obvi- 
ous phylogenetic diversity, these agents are unlikely to 
share a single common mechanism of induction of disease. 
It seems more likely in our opinion that the host response 
to a viral infection of the central nervous system (CNS) is 
the common thread that ties together these seemingly dis- 
parate infections. Consideration of the mechanism of 
induction of demyelinating disease must consider several 
mutually non-exclusive alternative mechanisms as summa- 
rized in Table 2. Moreover, the pathogenic response to a 
viral infection might resemble in many aspects the effector 
mechanisms observed in the autoimmune model, experi- 
mental allergic encephalomyelitis (EAE). A fundamental 
difference in the viral and EAE models is that of the infec- 
tions etiology; infection is a necessary requirement of 
demyelination in the viral models, and it is precisely this 
cause-effect relationship that makes these viral models 
attractive platforms to explore the etiology and pathogen- 
esis of demyelinating disease. 
Table 2 
Potential mechanisms of demyelination induced by MHV. 
Potential mechanism Examples References 
Virus persistence Disrupts oligodendrocyte function [371 
In astrocytes, results in chronic [I41 
INOS, TNF-a and IL-6 expression 
and glial toxicity 
Persistent viral antigens expressed [23’*,24”] 
in glial cells target chronic immune 
response to white matter 
Molecular mimicry Virus infection primes immune [36,381 
response to cross-reactive 
myelin antigens such as MBP 
or PLP 
INOS, inducible NOS; MBP, myelin basic protein; PLP, proteolipid 
protein. 
This brief review emphasizes recent advancements that 
have contributed to our understanding of how viruses con- 
tribute to developing neuropathology following infection of 
the CNS. Viral-CNS disease models are numerous and com- 
plex, however, for this discussion we have focused our 
attention upon two of the most widely used models of virus- 
induced demyelination: Theiler’s murine encephalomyelitis 
virus and mouse hepatitis virus. 
Viral models of demyelinating disease 
The mouse hepatitis virus (MHV) model provides a unique 
probe that has proven useful in interpretation of demyeli- 
nating disease. Coronaviruses are an ubiquitous group of 
positive stranded RNA viral pathogens of man and animals 
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Figure 1 
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Infection of adult mice with the MHV-JHM virus. (a) Time course of 
viral infection and demyelination following infection with a 
demyelinating variant of MHV-JHM. Free virus is evident for only 
1 O-l 5 days post-infection; however, demyelination persists for greater 
than 50 days. (b) Foci of demyelination are characteriied by the 
co-localization of viral RNA (top left) and demyelinating white matter 
lesions (top right). Late lesions show extensive demyelination active 
macrophage phagocytosis of myelin debris (bottom left, arrow) and the 
presence of demyelinating axons (bottom right, arrows). 
associated with a wide spectrum of respiratory, gastroin- 
testinal and neurological diseases. Infection of adult mice 
with the MHV-JHM strain of the virus elicits a reproducible 
syndrome characterized by an early peak of virus replica- 
tion in the brain, followed by an acute T-cell-dependent 
demyelinating encephalomyelitis involving both brain and 
spinal cord (Figure 1). Active viral replication is controlled 
early in the MHV model: by lo-15 days after infection viral 
titers have dropped below the limit of detection, although 
viral RNA persists in white matter for several months. 
Notable is the uncoupling of early viral replication and later 
induction of demyelination. This pattern is in sharp con- 
trast to the Theiler’s murine encephalomyelitis virus 
(TMEV) model in which infection is followed by a produc- 
tive persistent infection of white matter. These viral 
models allow investigation into the details of the virus-host 
interaction that lead to disease. 
Nitric oxide and CNS disease 
The gaseous free-radical nitric oxide (NO) is generated 
through the action of one of three isoforms of the enzyme 
nitric oxide synthase (NOS). NOSl and NOS3 are 
expressed constitutively resulting in low-level output of 
NO [Z]. These two enzymes function primarily in the 
maintenance of tissue homeostasis, as well as vasoregula- 
tion. In contrast, NOSZ (inducible NOS or iNOS) 
transcripts are expressed following exposure of a wide vari- 
ety of cells to cytokines or bacterial endotoxin. Therefore, 
under proinflammatory conditions arising from either 
microbial infection and/or injury, NOSZ expression is often 
detected and considered an important contributor to the 
pathogenesis of a wide variety of inflammatory diseases. 
The CNS is not exempt from expression of NO%?. High- 
level expression of the gene encoding NO%? has been 
detected in numerous neuropathologies including MS [3] 
and Alzheimer’s disease [4]. Furthermore, NOS’2 has been 
detected within the CNS following infection with a wide 
variety of both DNA and RNA viruses [5]. Within the 
CNS, astrocytes and microglialmacrophages are the pre- 
dominant cellular sources of NOS’Z [6,7]. Although the 
contributions of NO generated by NO%? to CNS damage 
are not fully understood, studies have demonstrated that 
NO exerts a cytotoxic effect on cultured oligodendrocytes 
suggesting that this free-radical might also contribute to 
demyelination in patients with MS [8]. In addition to a 
direct cytotoxic effect, NO can interact with superoxide 
anion (O,-) to form peroxynitrate anion, which is a strong 
oxidant that might contribute to pathology of neurodegen- 
erative diseases [9’,10]. 
NOS.2 is detected within brains and spinal cords of mice 
during both acute and chronic stages of infection with both 
TMEV and MHV [6,7,11,12’,13,14]. Astrocytes and cells 
of the monocyte/macrophage lineage were found to 
express the NOSZ gene in both viral infections [6,7,12’]. 
Within TMEV-infected mice, both astrocytes and 
macrophage/monocytes stained positive for NO%? during 
acute and chronic stages of disease. In contrast, within 
MHV-infected mice the cellular source of NO% was 
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dependent upon the stage of disease. During the acute 
meningoencephalitis period (5-7 days post-infections), 
inflammatory macrophages were the predominant source 
of NO%? transcripts and protein, while astrocytes almost 
exclusively expressed NOS’2 during the chronic demyeli- 
nating stages of disease [6,7]. These observations suggest 
that the stage of disease (i.e. acute versus chronic) might 
dictate the contributions of NO to the disease process. 
Administration of aminoguanidine (AG - a selective 
inhibitor of NOSZ activity) to either TMEV- or MHV- 
infected mice resulted in a marked reduction in the 
severity of clinical disease, as weh as inflammation and 
demyelination, suggesting a role for NO% generated NO 
in the pathologies of these CNS infections [14]. This AG 
treatment did not affect viral replication or the ability of the 
animals to clear virus indicating that the reduction in the 
severity of disease was due to inhibition of NO% activity 
rather than an indirect effect. The mechanism(s) by which 
NO might contribute to these diseases is unknown. In addi- 
tion to its well demonstrated cytotoxic effects (alone or in 
combination with O,-), NOSZ generated NO may con- 
tribute to neurologic disease in a subtler manner. 
Administration of AG to MHV-infected mice was found to 
result in a selective decrease in the level of mRNA tran- 
scripts for monocyte chemoattractant protein-l (MCP-l), 
which is a C-C chemokine that is thought to function in 
attracting both T cells and macrophages during inflamma- 
tory conditions [15’,16]. Therefore, it is possible that NO 
generated by NOSZ might contribute to CNS disease by 
promoting transcription of pro-inflammatory factors. 
Cytokineslchemokines and CNS disease 
CNS infection with a wide variety of different viruses 
results in increased local expression of both cytokines and 
chemokines. Production of these soluble mediators by 
activated T cells, macrophages and resident glia (e.g. astro- 
cytes, oligodendrocytes and microglia) allows for a variety 
of responses including the initiation and maintenance of an 
inflammatory response through induction of adhesion mol- 
ecule expression by endothelial cells, and increased 
expression of cytokine and chemokine receptors by infil- 
trating cells. Furthermore, production of these factors 
allows for cell-to-cell communication that might be impor- 
tant in controlling cell proliferation, antigen presentation, 
and production of potentially toxic products [17,18]. 
Both MHV and TMEV induce expression of cytokine and 
chemokine genes following infection of the mouse CNS. 
Cytokine genes that are expressed during acute MHV infec- 
tion (between days 5-7 post-infections) of the CNS include 
interferons alpha, beta, and gamma (IFN-a, B, r), tumor 
necrosis factor-alpha (TNF-a), interleukins 1 alpha and beta, 
(IL-la and B), IL-Z, IL-6, and IL-12 [f&19,20]. Although this 
profile indicates a T helper cell type 1 (Thl) profile is preva- 
lent during infection, mRNA transcripts for IL-4 and IL-10 
can be detected suggesting that a polarized Thl or Th2 
response is occurring. Furthermore, the severity of infection 
does not appear to dictate the cytokine response within the 
CNS. In other words, similar cytokine profiles are obtained 
when the highly neurovirulent MHV-JHM or attenuated 
strains are used for experimental infection. Similarly, CNS 
infection by TMEV results in a predominantly Thl cytokine 
profile (e.g. IFN-y, TNF-a, and IL-Z) that did not appear to 
be strain dependent [Zl]. 
In addition to cytokines, members of both the C-C and C- 
X-C family of chemokines [ZZ] are also expressed in the 
brains and spinal cords of MHV-infected mice; for example, 
the C-X-C chemokines genes encoding the cytokine 
response gene-Z/interferon inducible protein-10 (CRG-Z/ 
IP-lo), MIG, and macrophage inflammatory protein-2 
(MIP-2) are up-regulated, and the C-C chemokines genes 
encoding MCP-1, MCP-3, MIP-1P and RANTES are also 
up-regulated [23”]. Although the role of these molecules in 
the pathogenesis of either the acute stage or the chronic 
stage of disease is unclear, it is conceivable that these mol- 
ecules function to attract inflammatory leukocytes into the 
CNS following viral infection. These inflammatory leuko- 
cytes then contribute to host defense by eliminating virus. 
Mechanisms of host defense against MHV infection of the 
CNS include the generation of perforin-dependent virus- 
specific cytotoxic T lymphocytes (CTLs) [24”]. Cytokines 
might also aid in host defense against MHV by contributing 
to the elimination of virus from the CNS. Recent studies 
demonstrate that IFN-y knock-out mice display higher 
mortality and increased viral burden within the CNS com- 
pared with age-matched control mice [ 131. Interestingly, 
the antiviral effect of IFN-y is dependent upon the host 
cells infected: IFN-y is not required for clearance of virus 
from neurons, but is of critical importance in clearance from 
oligodendrocytes [24”]. This is interesting in that these 
observations suggest separate, distinct mechanisms exist 
within the CNS that contribute to viral clearance. 
In addition to their potential role in antiviral immunity, 
cytokines and chemokines might also contribute to CNS 
pathology in animals persistently infected with MHV 
Chronic expression of these factors may ultimately lead to 
deleterious effects by triggering the chronic release of 
toxic molecules such as NO. Cytokines that are expressed 
in the spinal cords of mice persistently infected with 
MHV include TNF-a, IL-6, and IL-1B [6]. These 
cytokines were localized primarily to white matter tracts 
associated with demyelination and MHV infection, and 
were produced predominantly by astrocytes. The majori- 
ty of cytokine-expressing astrocytes, however, were not 
infected with MHV suggesting that activation and 
cytokine secretion is not due to viral infection. 
A recent study reports that the anti-inflammatory cytokine 
IL-10 has no substantial role in contributing to either viral 
clearance or demyelination in MHV-infected mice. A sub- 
set of IL-lo-/- mice, however, did exhibit a moderate 
increase in the number of inflammatory mononuclear cells 
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compared with control mice, suggesting that IL-10 may 
exert some minor control of inflammation during acute 
stages of disease [ZS]. 
Individually, cytokines might contribute to demyelination 
by increasing vascular permeability, sustaining T cell 
responses, or increasing the expression of adhesion mole- 
cules [14,18]. Alternatively, these cytokines might work in 
concert with one another to enhance the inflammatory 
response, as well as to activate cells to express cytotoxic mol- 
ecules. Although TNF-a has been postulated to contribute 
to demyelination in both EAE and patients with MS, pas- 
sive administration of neutralizing antibodies to TNF-a did 
not diminish MHV-induced demyelination indicating that 
TNF-r~ does not play a dominant role in this infection [26]. 
The chemokines CRG-Z/IP-10 and RANTES are 
expressed most abundantly in the spinal cords of chronical- 
ly infected mice with demyelination [23”]. Similar to what 
has been reported with cytokines, expression of these 
chemokines was localized to areas of virus persistence and 
demyelination. CRG-Z/IP-10 was produced predominantly 
by uninfected astrocytes. 1n vitro studies have also demon- 
strated that MHV infection of astrocytes, as well as brain 
endothelial cells, results in cytokine and chemokine gene 
expression [23”,27]. Further characterization of the role(s) 
of these multipotent factors in MHV-induced demyelina- 
tion remains to be determined. Recent reports [Z&28**], 
however, have suggested a potential role for RANTES in 
the pathogenesis of MS since inflammatory leukocytes 
have been reported to be present within MS plaque lesions. 
Whether RANTES has a role in contributing to virus- 
induced demyelinating disease has yet to be determined. 
T cells and demyelination 
One theory for the underlying pathological mechanism in 
MS patients is that activated, myelin-specific CD4+ T cells 
secrete cytokines and chemokines, which function to 
attract inflammatory cells into the CNS and/or activate 
inflammatory cells and resident glia to produce factors that 
might be toxic to oligodendrocytes. Studies from animal 
models support the idea that T cells are important contrib- 
utors to the demyelination [29]. For example, in the well 
characterized autoimmune demyelination model, EAE, 
demyelination has been shown to be mediated by neu- 
roantigen-specific major histocompatibility complex 
(MHC) class II restricted T cells [29,30]. 
T lymphocytes (both CD4+ and CDB+ subsets) have been 
shown to contribute to the pathogenesis of TMEV induced 
demyelination. A recent report by Murray et al. [31’] has 
demonstrated that CD4+ and CDB+ T cells have distinct, 
nonredundant roles contributing to host defense and chronic 
demyelination disease following TMEV infection of the 
mouse CNS. The severity, however, of neurologic disease 
and demyelination was markedly enhanced in mice lacking 
CD4 antigen (CD4---) compared with CD8-/- or control 
mice suggesting that these cells might exert a protective 
effect during the course of disease. 
The contribution of T cells to demyelination in MHV- 
infected mice is unclear and remains controversial. 
Although studies have reported that T cells are essential for 
demyelination, other work has shown that demyelination 
occurs when either CD4+ or CDB+ T cells are depleted 
[32-351. The authors [34], however, state that their experi- 
mental results do not exclude the possibility that T cells 
might be important in initiating demyelination early in the 
infection. Houtman and Fleming [33] have reported that a 
percentage of either A,p ko mice (lacking MHC class II and 
have low numbers of CD4+ T cells) or p2 microglobulin ko 
mice (lacking MHC class I and have low numbers of CDB+ 
T cells) developed demyelination following infection with 
the MHV-JHM strain indicating that neither T cell subset 
is required for demyelination to occur. 
Conclusions 
It appears evident to us that continued presence of a viral 
genetic signal as either a replicating virus (i.e. in TMEV 
infection) or a persistent viral RNA and protein (i.e. in MHV 
infection) serves to drive the chronic inflammatory response 
in these models. Following TMEV infection anti-self reac- 
tivity has been observed as epitope spreading; reactivity 
with self antigens expressed on proteolipid protein (PLP) of 
myelin [36]. This anti-self reactivity might serve to amplify 
the intensity of white matter damage. However, a parallel 
anti-self reactivity has not been reproducibly described in 
the MHV model, and, therefore, it does not appear to be 
requisite for demyelination. Moreover, the MHV model 
presents an interesting challenge in answering the central 
question concerning what are the mechanisms of viral RNA 
persistent in the absence of viral replication. This paradigm 
would appear to fit the observation in MS of an early infec- 
tion linked to later disease and influenced by genetically 
determined host response. 
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